BERLIN--(BUSINESS WIRE)--The biotech company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) today announced that it has entered into a collaboration agreement with The University of Texas MD Anderson Cancer Center (MD Anderson). The agreement relates to a phase I trial with MOLOGEN’s immunomodulator lefitolimod (MGN1703) in combination with the immunotherapy Yervoy® (ipilimumab) in patients with advanced solid malignancies. This is the first time that lefitolimod (MGN1703) will be evaluated in combination with a checkpoint inhibitor. Should MGN1703 succeed in augmenting the efficacy of immune checkpoint blockade, the potential applications of the compound could be broadened. This study has been initiated based on the idea that the combination of these two immunotherapies could have synergistic effects by a broader activation of the immune system.